Impact of Bevacizumab on Symptom Burden and Neurological Deficits in Patients With Recurrent Glioblastoma

Impact of Bevacizumab on Symptom Burden and Neurological Deficits in Patients With Recurrent GBM: A Retrospective Patient Chart Review

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04974983

Enrollment

203

Registered

2021-07-23

Start date

2017-09-01

Completion date

2020-08-30

Last updated

2021-07-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Angiogenesis, Glioblastoma

Keywords

Glioblastoma, Angiogenesis

Brief summary

This retrospective non - interventional patient chart review will be utilizing real world clinical data from patients treated for rGBM at the University Regensburg Medical center either with or without bevacizumab. Only patients will be analyzed who were potentially eligible for bevacizumab treatment. The study is designed to investigate the potential effects of bevacizumab treatment on the functional status, symptom burden, neurological deficits, time to tumor progression and overall survival between cohorts potentially eligible for bevacizumab.

Interventions

OTHERObservation of neurological deficits

Observation of neurological deficits

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Diagnosis of recurrent glioblastoma

Exclusion criteria

Severe neurocognitive deficits

Design outcomes

Primary

Measure	Time frame	Description
Functional outcome	15 months	Neurological deficits impacting functional independency

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026